At the time of his death, Blume was recruiting patients for several clinical trials involving hematopoietic stem cells.
You are here
Coverage of the latest news and updates from the field of stem cells and regenerative medicine.
The new approach, not yet tested in patients, involves isolating cells from banked donor corneas to grow replacement corneal tissue in the lab. The advantage is that cells from a single donor could potentially benefit multiple patients with impaired vision.
The product, SB623, is being delivered to the damaged region of the brains of people who have suffered an ischemic stroke, which results from an obstruction within a blood vessel supplying blood to the brain. Ischemic strokes account for 87 percent of all stroke cases.
The work is important because networks of new blood vessels, assembled in the lab for transplanting into patients, could be a boon to those whose circulatory systems have been damaged by heart disease, diabetes and other illnesses.
He filed his lawsuit in California this week against the Nobel Assembly at Karolinska Institute. Dr. Xu is currently is chairman of MEBO International Group, a private enterprise engaged in life science that he founded in 1987. MEBO has offices in Beijing and in Arcadia, California.
Together the studies could lead to a way to help the heart regeneration itself following a heart attack, and offer new hope for the 17 million people who die from cardiovascular disease each year.